NCT07160257View on ClinicalTrials.gov

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 5, 2025

Primary Completion Date

August 26, 2026

Study Completion Date

December 13, 2026

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Maridebart cafraglutide

Maridebart cafraglutide will be administered SC.

DRUG

Placebo

Placebo will be administered SC.

Trial Locations (1)

91911

RECRUITING

ProSciento, Chula Vista

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT07160257 - A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter